Aclaris Therapeutics, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2021-03-01

Reporting Person: Gordon David N. (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	20600	—	Acquired	108135	Direct
2021-03-01	Common Stock	F	5660	$24.06	Disposed	102475	Direct
2021-03-02	Common Stock	M	8297	—	Acquired	110772	Direct
2021-03-02	Common Stock	F	2280	$23.25	Disposed	108492	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Employee Stock Option (Right to Buy)	$24.06	A	99500	Acquired	2031-02-28	Common Stock (99500)	Direct
2021-03-01	Restricted stock units	$	A	28400	Acquired		Common Stock (28400)	Direct
2021-03-01	Restricted stock units	$	M	20600	Disposed		Common Stock (20600)	Direct
2021-03-02	Restricted stock units	$	M	8297	Disposed		Common Stock (8297)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.

F3: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date.

F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.